The Oncology Institute, Inc.
TOI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.00 | -7.86 | 1.77 |
| FCF Yield | -130.78% | -27.17% | -56.02% | -5.53% |
| EV / EBITDA | -1.80 | -4.36 | -3.17 | -12.65 |
| Quality | ||||
| ROIC | -47.23% | -42.58% | 57.65% | -24.86% |
| Gross Margin | 13.73% | 18.37% | 20.63% | 20.12% |
| Cash Conversion Ratio | 0.50 | 0.44 | -406.29 | 2.99 |
| Growth | ||||
| Revenue 3-Year CAGR | 15.93% | 16.89% | 10.42% | 9.31% |
| Free Cash Flow Growth | 25.82% | 39.24% | -88.33% | -5,108.02% |
| Safety | ||||
| Net Debt / EBITDA | -1.37 | -1.59 | -1.39 | 2.71 |
| Interest Coverage | -8.02 | -11.36 | -20.08 | -143.31 |
| Efficiency | ||||
| Inventory Turnover | 33.81 | 19.35 | 21.64 | 25.19 |
| Cash Conversion Cycle | 29.80 | 47.27 | 58.25 | 17.67 |